All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Sunitinib in pediatric patients with advanced gastrointestinal stromal tumor: results from a phase I/II trial

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F19%3A00070873" target="_blank" >RIV/65269705:_____/19:00070873 - isvavai.cz</a>

  • Result on the web

    <a href="https://link.springer.com/content/pdf/10.1007%2Fs00280-019-03814-5.pdf" target="_blank" >https://link.springer.com/content/pdf/10.1007%2Fs00280-019-03814-5.pdf</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1007/s00280-019-03814-5" target="_blank" >10.1007/s00280-019-03814-5</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Sunitinib in pediatric patients with advanced gastrointestinal stromal tumor: results from a phase I/II trial

  • Original language description

    BackgroundSunitinib is approved for treatment of adults with imatinib-resistant gastrointestinal stromal tumor (GIST) or imatinib intolerance.MethodsThis single-arm, multicenter, multinational phase I/II clinical trial (NCT01396148) enrolled eligible patients aged 6 to &lt;18years with advanced, unresectable GIST with non-mutant KIT, or who demonstrated disease progression or intolerance to imatinib. Patients received sunitinib 15mg/m(2) per day, 4-weeks-on/2-weeks-off (schedule 4/2), for 18 cycles over 24months. Intra-patient dose escalation to 22.5 and subsequently 30mg/m(2) were permitted based on individual patient tolerability and supported by real-time pharmacokinetics (PK). Primary objective was PK characterization. Secondary objectives included safety, antitumor activity and PK/pharmacodynamic relationships.ResultsSix patients were enrolled with median (range) age of 14 (13-16) years. All six patients completed at least three treatment cycles, with one completing all 18 cycles. Five patients had a dose increase to 22.5mg/m(2); two of them had a further dose increase to 30mg/m(2). The average daily dose at cycle 3 was 21.1mg/m(2) (n=6). Steady-state plasma concentrations were reached by day 15, cycle 1. No tumor responses were observed, but three patients had stabilization of the disease (50%). Median progression-free survival was 5.8months (95% CI 2.3not reached). There were no serious adverse events.ConclusionsThe tolerable dose of sunitinib in chemotherapy-naive pediatric patients is at least 20mg/m(2) on schedule 4/2. The safety profile and PK of sunitinib in pediatric patients with GIST are comparable to those in adults.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30104 - Pharmacology and pharmacy

Result continuities

  • Project

  • Continuities

    N - Vyzkumna aktivita podporovana z neverejnych zdroju

Others

  • Publication year

    2019

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Cancer chemotherapy and pharmacology

  • ISSN

    0344-5704

  • e-ISSN

  • Volume of the periodical

    84

  • Issue of the periodical within the volume

    1

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    10

  • Pages from-to

    41-50

  • UT code for WoS article

    000471238200004

  • EID of the result in the Scopus database

    2-s2.0-85064668514